Compare MOFG & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOFG | URGN |
|---|---|---|
| Founded | 1934 | 2004 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.6M | 922.1M |
| IPO Year | N/A | N/A |
| Metric | MOFG | URGN |
|---|---|---|
| Price | $49.17 | $20.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $40.50 | $29.50 |
| AVG Volume (30 Days) | 204.8K | ★ 665.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $242.68 | $26.47 |
| Revenue Next Year | $7.66 | $110.65 |
| P/E Ratio | $17.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.62 | $3.42 |
| 52 Week High | $49.69 | $30.00 |
| Indicator | MOFG | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 75.63 | 47.30 |
| Support Level | $47.16 | $19.65 |
| Resistance Level | $49.26 | $21.62 |
| Average True Range (ATR) | 1.22 | 1.33 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 92.35 | 45.26 |
MidWestOne Financial Group Inc is a bank holding company engaged in delivering relationship-based business and personal banking products and services. The Bank provides commercial loans, real estate loans, agricultural loans, credit card loans, and consumer loans. It also provides deposit products including demand and interest checking accounts, savings accounts, money market accounts, and time deposits. The Bank also provides products and services including treasury management, Zelle, online and mobile banking, debit cards, ATMs, and safe deposit boxes. The Bank offers its products and services through its network of full-service banking offices. the Bank's investments services department offers financial planning, investment advisory, and retail securities brokerage services.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.